Protein kinase C, p38 MAPK, and Involucrin (PKC/p38/IVL)

The grouping of Protein Kinase C (PKC), p38 Mitogen-Activated Protein Kinase (p38 MAPK), and Involucrin represents a critical signaling axis rather than a single therapeutic target. This pathway is primarily recognized for its role in the terminal differentiation of epidermal keratinocytes. In this cascade, specific PKC isoforms (such as PKC-delta or PKC-eta) activate the p38 MAPK pathway, which in turn stimulates the expression of Involucrin, a structural protein essential for forming the protective cornified envelope of the skin (PubMed: 10411908, UniProt: P07476). Dysregulation of this axis is frequently observed in hyperproliferative skin disorders like psoriasis and skin cancers such as squamous cell carcinoma, where the normal maturation process of skin cells is disrupted (PubMed: 15661748). While individual components like p38 MAPK have been targeted by small molecule inhibitors in clinical trials, the entire axis is often used as a pharmacological model to evaluate the efficacy of topical treatments aimed at restoring skin barrier function and normal differentiation. Because this entry combines two distinct enzyme families and a structural protein, it is considered a pathway or a set of related biomarkers rather than a discrete molecular target.

Other names

PKC-p38-Involucrin signaling axisKeratinocyte differentiation pathwayPKC-p38 MAPK-IVL pathway

Activation of Protein Kinase C (PKC) isoforms leads to the downstream phosphorylation and activation of p38 Mitogen-Activated Protein Kinase (p38 MAPK), which subsequently induces the transcription and expression of Involucrin, a key structural component of the keratinocyte cornified envelope.